There are no approved drugs which act on fibrosis for any systemic disease

We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening chronic diseases, by developing innovative therapies underpinned by scientific excellence.

Our novel class of drugs has the potential to be an essential therapy in the treatment of serious inflammatory and fibrotic diseases, including chronic kidney disease, focal segmental glomerulosclerosis, scleroderma, diabetic retinopathy and other diseases.

Our mission is to advance these novel therapeutics through clinical development to provide precision medicine treatments for these conditions.

OccuRx is a biopharmaceutical company focused on developing revolutionary precision therapies for diseases associated with inflammation and fibrosis.

OccuRx has identified and validated a series of lead candidates against novel targets and established preclinical proof of concept to treat and prevent fibrosis, which accounts for 45% of all causes of deaths globally.

OCX063 is Occurx’s lead small drug candidate molecule that targets a novel receptor, which has been previously shown to mediate signalling pathways associated with inflammation and fibrosis in the development and progression of fibrotic diseases of the kidney, heart, lung, and intestine.

With a shared mission, OccuRx works closely with fellow Australian biotech company Certa Therapeutics.

Together, we’re developing a treatment platform for a broad spectrum of inflammatory and fibrotic diseases.

OccuRx and Certa Therapeutics are supported by common investment partners, led by Brandon BioCatalyst and Uniseed.

Since its inception in 2015, OccuRx has secured over $28m from Australian investors led Brandon Biocatalyst & Uniseed